Revenue by Segment:

• Biopharmaceutical Services: 70%
• Research and Development (R&D): 20%
• Manufacturing and Production: 10%

TOP 3 Markets and their Percentage Shares:

• USA: 45%
• China: 30%
• Europe: 15%

WuXi Biologics generates the majority of its revenue from biopharmaceutical services, accounting for approximately 70% of total revenue. This includes services such as the development and manufacturing of biologics. The research and development segment contributes 20%, while manufacturing and production make up the remaining 10%.

Geographically, the U.S. market is the largest, accounting for 45% of revenue, followed by China at 30% and Europe at 15%. This distribution reflects WuXi Biologics' strong presence in the U.S. as well as the growing importance of the Chinese market.

Production sites of WuXi Biologics:

• China: Multiple sites, including Wuxi, Shanghai, and Suzhou.
• Ireland: Dundalk.
• Germany: Leverkusen.
• USA: Massachusetts.

In recent years, WuXi Biologics has significantly expanded its production capacities. In China, the company operates several state-of-the-art facilities specializing in the manufacturing of biopharmaceuticals.

In Ireland, a large production facility has been established in Dundalk, which is considered one of the largest facilities of its kind in Europe. This expansion into Europe and the USA underscores the company's global growth strategy to offer its services worldwide and increase proximity to its international customers.

Revenue Growth: 20% (2024) Investment in R&D: 30% of revenue (2024)

WuXi Biologics pursues a strategy of sustainable growth through significant investments in research and development. The company plans to further expand its capacities in the field of biologics production to meet the increasing demand.

Another focus is on geographical expansion, particularly in the markets of North America and Europe. Through strategic partnerships and acquisitions, WuXi Biologics aims to strengthen its global presence and attract new customers.

Additionally, the company is focusing on technological innovations to increase efficiency and quality in production. This includes the use of advanced bioprocess technologies and the digitization of production processes.

Main raw materials: Biological raw materials, chemicals, laboratory equipment

Countries of origin: USA, Germany, China

WuXi Biologics imports a variety of raw materials and materials necessary for biopharmaceutical production. These include biological raw materials such as cell lines and proteins, which are often sourced from the USA and Germany, as these countries are leading in biotechnological research and production.

In addition, the company imports special chemicals and laboratory equipment needed for research and development as well as the production of biologics. These materials often come from China, which has a well-developed chemical industry and offers cost-effective production capabilities.

The combination of these international sources enables WuXi Biologics to produce high-quality products while remaining competitive.

Market share: 10% (estimated, 2025)
R&D investments: 20% of revenue (2024)
Customer retention: 85% (2024)

WuXi Biologics (Cayman) Inc. has a significant competitive advantage in the biopharmaceutical industry, especially through its comprehensive services in biologics development and manufacturing. The company benefits from a diversified customer base and high customer retention, indicating the quality and reliability of its services.

Another key advantage is the high investment in research and development, which accounts for about 20% of revenue. These investments enable WuXi Biologics to develop innovative technologies and continuously improve their services, strengthening their market position.

Additionally, through strategic partnerships and global presence, WuXi Biologics has enhanced its competitiveness. Together, these factors give the company a strong competitive edge in a dynamic and growing market.

Institutional Investor Share: approx. 70% (2025, estimated based on historical data)

Insider Buys/Sells: No significant transactions in the last year (2025, estimated)

The institutional investor share at WuXi Biologics is traditionally high, as the company is considered a leading provider of services in the biotechnology industry and therefore attractive to institutional investors.

Regarding insider buys and sells, there have been no significant transactions in the last year, indicating stable confidence from management in the long-term development of the company. This can also be seen as a sign that no significant internal changes or uncertainties are expected.

Market Share of WuXi Biologics: Estimated 12% (2025)

Top Competitors and Their Market Shares:

1. Lonza Group AG: 15%
2. Samsung Biologics: 14%
3. WuXi Biologics (Cayman) Inc.: 12%
4. Catalent, Inc.: 10%
5. Boehringer Ingelheim BioXcellence: 8%
6. Thermo Fisher Scientific (Patheon): 7%
7. Sartorius Stedim Biotech: 6%
8. Fujifilm Diosynth Biotechnologies: 5%
9. AGC Biologics: 4%
10. Rentschler Biopharma SE: 3%

Moat of WuXi Biologics:

WuXi Biologics has a significant moat due to its comprehensive platform for contract research, development, and manufacturing services (CRDMO) in biologics. The ability to offer end-to-end solutions, from early research to commercial production, gives the company a competitive advantage. Additionally, WuXi Biologics benefits from its strong presence in China, one of the fastest-growing markets for biologics.

Compared to its competitors, WuXi Biologics has an advantage in the speed and flexibility with which it can execute projects. This is particularly important in the biotechnology industry, where time is a critical factor. However, companies like Lonza and Samsung Biologics also have strong moats, especially through their global reach and established partnerships with large pharmaceutical companies.

Overall, WuXi Biologics has a significant moat, which is, however, mitigated by strong competition and their own advantages. The ability to continuously innovate and increase efficiency will be crucial to maintaining and expanding the moat.

Revenue Growth: 18% (2024) R&D Investments: 12% of revenue (2024) Market Share in CDMO Sector: 10% (2024)

In 2024, WuXi Biologics achieved a revenue growth of 18%, driven by increasing demand for its contract development and manufacturing services (CDMO). The company continues to heavily invest in research and development, allocating 12% of its revenue to expand its technological capabilities and offer innovative solutions.

WuXi Biologics holds a 10% market share in the CDMO sector, positioning the company as one of the leading providers in this field. This strong market position allows WuXi Biologics to benefit from the growing outsourcing trend in the biopharmaceutical industry.

Overall, WuXi Biologics demonstrates solid growth potential, supported by strategic investments and a strong market position. This could make the stock an attractive investment, especially for investors interested in long-term growth in the biotechnology sector.

Dividend payment: No dividend (as of 2025)

WuXi Biologics (Cayman) Inc. has not distributed any dividends to its shareholders so far. The company typically reinvests its profits in the growth and expansion of its business model, especially in research and development, as well as in expanding its production capacities.

The reliability of a dividend payment is therefore not guaranteed, as the company currently does not make any distributions. Investors who invest in WuXi Biologics usually do so because of the growth potential and not because of a dividend yield.